Oral Non-Viral Gene Delivery for Applications in DNA Vaccination and Gene Therapy.

[1]  M. Chiriva-Internati,et al.  Development of a M cell-targeted microparticulate platform, BSK02™, for oral immunization against the ovarian cancer antigen, sperm protein 17. , 2019, Journal of biomedical materials research. Part B, Applied biomaterials.

[2]  D. Vllasaliu,et al.  Chitosan nanoparticle antigen uptake in epithelial monolayers can predict mucosal but not systemic in vivo immune response by oral delivery. , 2018, Carbohydrate polymers.

[3]  Xin Zhang,et al.  Strategies and industrial perspectives to improve oral absorption of biological macromolecules , 2018, Expert opinion on drug delivery.

[4]  K. Whitehead,et al.  Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract , 2018, Scientific Reports.

[5]  W. Yuan,et al.  Targeted Delivery of GP5 Antigen of PRRSV to M Cells Enhances the Antigen-Specific Systemic and Mucosal Immune Responses , 2018, Front. Cell. Infect. Microbiol..

[6]  S. Stibitz,et al.  Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a , 2017, Clinical and Vaccine Immunology.

[7]  I. Park,et al.  Oral siRNA Delivery to Treat Colorectal Liver Metastases. , 2017, ACS nano.

[8]  Dong Yun Lee,et al.  Oral delivery of a therapeutic gene encoding glucagon‐like peptide 1 to treat high fat diet‐induced diabetes , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[9]  Ying Zhu,et al.  Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4+ and CD8+ T-cell Responses , 2017, Cancer Immunology Research.

[10]  H. Weiner,et al.  History and mechanisms of oral tolerance. , 2017, Seminars in immunology.

[11]  S. Xiong,et al.  Incorporation of a bi‐functional protein FimH enhances the immunoprotection of chitosan‐pVP1 vaccine against coxsackievirus B3‐induced myocarditis , 2017, Antiviral research.

[12]  A. Pannier,et al.  Chitosan‐zein nano‐in‐microparticles capable of mediating in vivo transgene expression following oral delivery , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[13]  V. Azevedo,et al.  A New Broad Range Plasmid for DNA Delivery in Eukaryotic Cells Using Lactic Acid Bacteria: In Vitro and In Vivo Assays , 2016, Molecular therapy. Methods & clinical development.

[14]  Lanlan Han,et al.  Heterologous expression of carcinoembryonic antigen in Lactococcus lactis via LcsB-mediated surface displaying system for oral vaccine development. , 2016, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[15]  N. Nafissi,et al.  Non-viral gene therapy: Gains and challenges of non-invasive administration methods. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[16]  S. Stibitz,et al.  Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery , 2016, PloS one.

[17]  Yuejun Kang,et al.  Combination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation , 2016, Theranostics.

[18]  G. Duan,et al.  An engineered Lactococcus lactis strain exerts significant immune responses through efficient expression and delivery of Helicobacter pylori Lpp20 antigen , 2016, Biotechnology Letters.

[19]  Shu-Lin Liu,et al.  Live attenuated Salmonella displaying HIV-1 10E8 epitope on fimbriae: systemic and mucosal immune responses in BALB/c mice by mucosal administration , 2016, Scientific Reports.

[20]  K. Maloy,et al.  The Mucosal Immune System and Its Regulation by Autophagy , 2016, Front. Immunol..

[21]  E. Malchiodi,et al.  A prime-boost immunization with Tc52 N-terminal domain DNA and the recombinant protein expressed in Pichia pastoris protects against Trypanosoma cruzi infection. , 2016, Vaccine.

[22]  P. Desai,et al.  Construction of a new shuttle vector for DNA delivery into mammalian cells using non-invasive Lactococcus lactis. , 2016, Microbes and infection.

[23]  A. Bowie,et al.  The Vaccine Adjuvant Chitosan Promotes Cellular Immunity via DNA Sensor cGAS-STING-Dependent Induction of Type I Interferons. , 2016, Immunity.

[24]  N. Peppas,et al.  Enzyme- and pH-Responsive Microencapsulated Nanogels for Oral Delivery of siRNA to Induce TNF-α Knockdown in the Intestine. , 2016, Biomacromolecules.

[25]  H. Ohno.  Intestinal M cells. , 2016, Journal of biochemistry.

[26]  Lichen Yin,et al.  Optimization of multifunctional chitosan-siRNA nanoparticles for oral delivery applications, targeting TNF-α silencing in rats. , 2015, Acta biomaterialia.

[27]  A. Miyoshi,et al.  Development of a new DNA vaccine based on mycobacterial ESAT-6 antigen delivered by recombinant invasive Lactococcus lactis FnBPA+ , 2014, Applied Microbiology and Biotechnology.

[28]  A. Moss,et al.  Review article: immunogenicity of anti‐TNF biologics in IBD – the role of patient, product and prescriber factors , 2013, Alimentary pharmacology & therapeutics.

[29]  A. Kaser,et al.  Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation , 2013, Gut.

[30]  N. Selvamurugan,et al.  Chitosan and its derivatives for gene delivery. , 2011, International journal of biological macromolecules.

[31]  M. Amiji,et al.  Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease , 2008, Gene Therapy.

[32]  D T. Page,et al.  Innovations in oral gene delivery: challenges and potentials. , 2001, Drug discovery today.

[33]  D. Kozbor,et al.  Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein. , 2000, Virology.

[34]  H. Greenberg,et al.  Protective Immunity Induced by Oral Immunization with a Rotavirus DNA Vaccine Encapsulated in Microparticles , 1998, Journal of Virology.